Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328489 | 1.00 | KMT2A (0.81) | KMT2AMAPK1MAPTLMNAALOX15 | |
| SCHEMBL8329901 | 1.00 | KMT2A (0.81) | KMT2AMAPK1MAPTLMNAALOX15 | |
| SCHEMBL8330227 | 1.00 | KMT2A (0.81) | KMT2AMAPK1MAPTLMNAALOX15 | |
| SCHEMBL28811693 | 1.00 | KMT2A (0.81) | KMT2AMAPK1MAPTLMNAALOX15 | |
| SCHEMBL9715621 | 1.00 | KMT2A (0.81) | KMT2AMAPK1MAPTLMNAALOX15 | |
| SCHEMBL523889 | 1.00 | KMT2A (0.81) | KMT2AMAPK1MAPTLMNAALOX15 | |
| SCHEMBL522715 | 1.00 | KMT2A (0.81) | KMT2AMAPK1MAPTLMNAALOX15 | |
| SCHEMBL523888 | 1.00 | KMT2A (0.81) | KMT2AMAPK1MAPTLMNAALOX15 | |
| SCHEMBL1263214 | 0.90 | KMT2A (1.00) | KMT2AMAPK1MAPTALOX15SMN1; SMN2 | |
| SCHEMBL739575 | 0.90 | KMT2A (1.00) | KMT2AMAPK1MAPTALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187478-B2 | Substituted naphthyridines and their use as medicaments | Boehringer Ingellheim International GmbH (DE) | 2015-11-17 | — | — | US | disclosed |
| EP-2528915-B1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2528915-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| EP-0559774-B1 | INDIVIDUAL STEREOISOMERS OF 7- 3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0909759-A2 | Individual stereoisomers of 7-(3-aminoalkyl)-1-pyrrolidinyl)-quinolones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5633264-A | Individual stereoisomers of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-Quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| US-5563155-A | QUINOLONE ANTIBIOTICS WITH INCREASED EFFICACY, REDUCED SIDE EFFECTS | WARNER-LAMBERT COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| US-5461165-A | Individual stereoisomers of intermediates of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| US-5344940-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1994-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | KMT2A 4357/4885MAPK1 3154/4885MAPT 4606/4885 |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | KMT2A 4357/4885MAPK1 3154/4885MAPT 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.